HomeComparePBIO vs CL

PBIO vs CL: Dividend Comparison 2026

PBIO yields 166666.67% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBIO wins by $11911377672882.58M in total portfolio value
10 years
PBIO
PBIO
● Live price
166666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11911377672882.62M
Annual income
$5,393,136,696,480,418,000.00
Full PBIO calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — PBIO vs CL

📍 PBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBIOCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBIO + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBIO pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBIO
Annual income on $10K today (after 15% tax)
$14,166,666.67/yr
After 10yr DRIP, annual income (after tax)
$4,584,166,192,008,355,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, PBIO beats the other by $4,584,166,192,008,350,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBIO + CL for your $10,000?

PBIO: 50%CL: 50%
100% CL50/50100% PBIO
Portfolio after 10yr
$5955688836441.33M
Annual income
$2,696,568,348,240,211,500.00/yr
Blended yield
45.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

PBIO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-50.4
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBIO buys
0
CL buys
0
No recent congressional trades found for PBIO or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBIOCL
Forward yield166666.67%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28.6%
Portfolio after 10y$11911377672882.62M$40.8K
Annual income after 10y$5,393,136,696,480,418,000.00$5,401.96
Total dividends collected$11310008644767.18M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: PBIO vs CL ($10,000, DRIP)

YearPBIO PortfolioPBIO Income/yrCL PortfolioCL Income/yrGap
1← crossover$8,344,033$8,333,333.33$11,012$312.01+$8.33MPBIO
2$3,258,162,280$3,249,234,164.07$12,196$412.95+$3258.15MPBIO
3$596,362,299,915$592,876,066,275.31$13,599$549.66+$596362.29MPBIO
4$51,347,407,585,706$50,709,299,924,797.41$15,288$736.64+$51347407.57MPBIO
5$2,095,186,069,772,327$2,040,244,343,655,621.00$17,353$995.28+$2095186069.75MPBIO
6$41,143,898,865,343,200$38,902,049,770,686,810.00$19,926$1,357.80+$41143898865.32MPBIO
7$401,002,058,588,188,860$356,978,086,802,271,700.00$23,194$1,873.82+$401002058588.17MPBIO
8$2,054,879,028,737,436,700$1,625,806,826,048,074,500.00$27,439$2,621.52+$2054879028737.41MPBIO
9$6,091,813,996,637,570,000$3,893,093,435,888,512,500.00$33,088$3,727.38+$6091813996637.54MPBIO
10$11,911,377,672,882,618,000$5,393,136,696,480,418,000.00$40,806$5,401.96+$11911377672882.58MPBIO

PBIO vs CL: Complete Analysis 2026

PBIOStock

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Full PBIO Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this PBIO vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBIO vs SCHDPBIO vs JEPIPBIO vs OPBIO vs KOPBIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.